Hematology & Blood Cancer
Hematology & Blood Cancer
Dustin SamplesLymphoma | February 15, 2023
A case series demonstrated the effectiveness of a novel trio for pediatric plasmacytic PTLD.
Read More
Dustin SamplesLeukemia | January 17, 2023
Adolescents and young adults face different challenges than older survivors of ALL. Can technology improve these challenges?
Leah LawrenceTreatment | January 10, 2023
Prognostic understanding is essential to medical decision-making, but are these patients' hopes too high?
Kate B. Hubbard, MSN, RN, OCN®, NPD-BCBest Practices | January 9, 2023
Accreditation and certification surveys validate an organization's quality of care. How can your organization be prepared?
Dustin SamplesHematology & Blood Cancer | January 6, 2023
Interprofessional team-based care is the standard for patients undergoing HSCT. But who belongs on the team?
Leah LawrenceHematology & Blood Cancer | October 12, 2022
Care teams at Thomas Jefferson University Hospital decreased time to chemotherapy administration by using new strategies.
Leah LawrenceHematology & Blood Cancer | September 20, 2022
ICANS, a complication of CAR T cell therapy, was associated with an injury that is detectable with a blood test.
Emily MenendezHematology & Blood Cancer | September 1, 2022
The tablet form of blood cancer drug acalabrutinib has been FDA approved, making administration easier for certain patients.
Teresa Hagan Thomas, PhD, RNTreatment | July 12, 2022
One concern that keeps patients from enrolling in clinical trials is the belief that their quality of life will suffer.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | June 27, 2022
Patients who receive a transplant at a young age may experience GVHD symptoms decades later, like oral chronic GVHD.
Patrick DalyHematology & Blood Cancer | March 24, 2022
Anti-thymocyte globulin (ATG) is used in conditioning prior to allogeneic hematopoietic stem cell transplantation for acute ...
Ariel JonesConferences | December 18, 2021
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Ariel JonesConferences | December 17, 2021
These findings were presented at the 2021 American Society of Hematology Annual Meeting.
Ariel JonesConferences | December 17, 2021
Hervé Tilly, MD, of Centre Henri Becquerel and University of Rouen in France, presented the new research at ASH 2021.
Ariel JonesConferences | December 16, 2021
This lack of benefit was seen in the entire study population.
Ariel JonesConferences | December 16, 2021
eripheral blood cytopenias may be associated with a higher risk of cancer-related mortality, particularly in Black patients.
Ariel JonesConferences | December 16, 2021
This is according to preliminary data from a nonrandomized arm of the SEQUOIA trial.
Ariel JonesConferences | December 16, 2021
The CAR T-cell therapy significantly improved event-free survival (EFS) compared with standard of care in patients with LBCL.
Ariel JonesConferences | December 14, 2021
According to new research, circulating tumor DNA (ctDNA) accurately reflects tumor burden.
Ariel JonesConferences | December 14, 2021
Investigator L. Elizabeth Budde, MD, PhD, presented the research at the 2021 ASH Annual Meeting.